Renoprotective Role of Metformin in Colistin-Induced Kidney Injury: A Dose-Dependent Study
Keywords:
Colistin, Nephrotoxicity, Metformin, Oxidative stress, Acute kidney injuryAbstract
Background: Colistin (polymyxin E) is a last-line antibiotic against Gram-negative infections, but its renal toxicity is limited by oxidative stress, NF-κB-mediated inflammation and tubular cell death. Metformin, a commonly used biguanide and AMPK activator, protects the kidney in many non-diabetic models of renal injury, but its effect on colistin-induced nephrotoxicity has not been studied.
Aims: To elucidate the oxidative, inflammatory and apoptotic pathways involved in the nephroprotective effects of low and high doses of metformin against colistin induced renal injury in rats.
Methods: Fifty adult male Wistar rats were randomly divided into 5 groups (n = 10): Control (saline), Colistin (15 mg/kg/day, i.p. from days 8 to 14), Metformin alone (200 mg/kg/day, orally), and 2 combination groups treated with colistin and low (100 mg/kg/day) or high (200 mg/kg/day) dose of metformin. Serum BUN and creatinine levels were determined by colorimetric method. Renal MDA, SOD, CAT, GSH and total protein concentrations were determined by ELISA. Renal mRNA expression of Bcl-2, Caspase-3, NF-κB, IL-18, Nrf2 and HO-1 were determined by qRT-PCR. The differences between the groups were analyzed using one-way ANOVA and Tukey’s post-hoc analysis.
Results: Colistin significantly increased BUN, serum creatinine, kidney MDA and decreased SOD, CAT, GSH and total protein levels (all P < 0.0001 vs. control). Colistin decreased Bcl-2, Nrf2 and HO-1 transcripts and increased Caspase-3, NF-κB and IL-18 levels (P < 0.0001). Metformin administration improved renal function, oxidative/antioxidant balance and gene expression in a dose dependent manner. The high-dose regimen (200 mg/kg/day) was superior to the low-dose regimen (100 mg/kg/day) in almost all the metrics (P < 0.05 to P < 0.0001), bringing most parameters back to control levels
Conclusions: Metformin dose-dependently protect against colistin-induced acute kidney injury via restoring Nrf2/HO-1 antioxidant route, suppressing NF-κB/IL-18-mediated inflammation and resetting Bcl-2/Caspase-3 apoptotic mechanism. These results imply that metformin might be used as an inexpensive nephroprotective supplement with colistin.